# Endovia Health Sciences, Inc.: overview EDVA · NYSE · CIK 1553788 · [Consumer staples](/sectors/consumer-staples.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/edva.md) · [Financials](/companies/edva/financials.md) · [Filings](/companies/edva/filings.md) · [Insiders](/companies/edva/insiders.md) Latest reported revenue: [$0](/filings/0001731122-26-001102.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 19, 2026 (XBRL us-gaap:Revenues, accession 0001731122-26-001102). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $k | [982](/filings/0001731122-25-001571.md) | [(2,768) d](/filings/0001731122-26-000577.md) | [68.6](/filings/0001731122-26-000769.md) | [(23.4) d](/filings/0001731122-26-001102.md) | [393 d](/filings/0001731122-25-001571.md) | [(365) d](/filings/0001731122-26-000577.md) | [4.2](/filings/0001731122-26-000769.md) | [0.0 d](/filings/0001731122-26-001102.md) | | Gross margin | % | [29.6%](/filings/0001731122-25-001571.md) | [29.6% d](/filings/0001731122-26-000577.md) | [37.2%](/filings/0001731122-26-000769.md) | [137.3% d](/filings/0001731122-26-001102.md) | [(6.1%) d](/filings/0001731122-25-001571.md) | [(13.0%) d](/filings/0001731122-26-000577.md) | [43.8%](/filings/0001731122-26-000769.md) | not reported | | Operating margin | % | [(271.9%)](/filings/0001731122-25-001571.md) | [10.5% d](/filings/0001731122-26-000577.md) | [(2417.1%)](/filings/0001731122-26-000769.md) | [6417.1% d](/filings/0001731122-26-001102.md) | [(2428.2%) d](/filings/0001731122-25-001571.md) | [267.4% d](/filings/0001731122-26-000577.md) | [(23176.4%)](/filings/0001731122-26-000769.md) | not reported | | Net margin | % | [(480.7%)](/filings/0001731122-25-001571.md) | [326.6% d](/filings/0001731122-26-000577.md) | [(5320.9%)](/filings/0001731122-26-001102.md) | [36285.9% d](/filings/0001731122-26-001102.md) | [(2515.1%) d](/filings/0001731122-25-001571.md) | [877.7% d](/filings/0001731122-26-000577.md) | [(50579.3%)](/filings/0001731122-26-001102.md) | not reported | | Diluted EPS | $ per share | not reported | not reported | [(1.97)](/filings/0001731122-26-000769.md) | not reported | not reported | not reported | [(0.47)](/filings/0001731122-26-000769.md) | not reported | | Free cash flow | $k | not reported | [(920) d](/filings/0001731122-26-000577.md) | not reported | not reported | not reported | not reported | not reported | not reported | - Revenue. XBRL Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure; 6-month figure less the 3-month figure; 9-month figure less the 6-month figure. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure; 6-month figure less the 3-month figure; 9-month figure less the 6-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure; 6-month figure less the 3-month figure; 9-month figure less the 6-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure; 6-month figure less the 3-month figure; 9-month figure less the 6-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquireProductiveAssets. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [11.3](/filings/0001731122-23-000543.md) | [18.1](/filings/0001731122-24-000539.md) | [18.9](/filings/0001731122-25-000964.md) | [0.8](/filings/0001731122-26-000577.md) | [0.1](/filings/0001731122-26-000577.md) | | Gross margin | % | [34.6%](/filings/0001731122-23-000543.md) | [32.7%](/filings/0001731122-24-000539.md) | [29.5%](/filings/0001731122-25-000964.md) | [(15.0%)](/filings/0001731122-26-000577.md) | [23.1%](/filings/0001731122-26-000577.md) | | Operating margin | % | [(257.0%)](/filings/0001731122-23-000543.md) | [(118.3%)](/filings/0001731122-24-000539.md) | [(81.1%)](/filings/0001731122-25-000964.md) | [(1235.6%)](/filings/0001731122-26-000577.md) | [(19415.6%)](/filings/0001731122-26-000577.md) | | Net margin | % | [(256.7%)](/filings/0001731122-23-000543.md) | [(119.9%)](/filings/0001731122-24-000539.md) | [(111.4%)](/filings/0001731122-25-000964.md) | [(2964.9%)](/filings/0001731122-26-000577.md) | [(34537.0%)](/filings/0001731122-26-000577.md) | | Diluted EPS | $ per share | [(1.02)](/filings/0001731122-22-000639.md) | not reported | not reported | [(17.68)](/filings/0001731122-26-000577.md) | [(11.97)](/filings/0001731122-26-000577.md) | | Free cash flow | $m | [(14.7)](/filings/0001731122-23-000543.md) | [(14.1)](/filings/0001731122-24-000539.md) | [(10.2)](/filings/0001731122-25-000964.md) | [(7.3)](/filings/0001731122-26-000577.md) | not reported | - Revenue. XBRL Revenue: us-gaap:Revenues. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:Revenues. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquireProductiveAssets. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/edva/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [HARBOUR INVESTMENTS, INC.](/funds/810121.md) | 2026-06-30 | $73 | 470 | | New +470 | ## Recent filings [All 431 filings](/companies/edva/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-27 | 17:26 ET | [S-1](/filings/0001731122-26-001378.md) | Registration statement | 0001731122-26-001378 | | 2026-10-27 | 16:10 ET | [8-K](/filings/0001731122-26-001375.md) | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0001731122-26-001375 | | 2026-10-15 | 16:10 ET | [8-K](/filings/0001731122-26-001347.md) | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0001731122-26-001347 | | 2026-10-06 | 16:10 ET | [8-K](/filings/0001731122-26-001320.md) | 3.02 Unregistered sale of equity | 0001731122-26-001320 | | 2026-10-05 | 16:31 ET | [DEF 14A](/filings/0001731122-26-001316.md) | Proxy statement, period 2026-10-05 | 0001731122-26-001316 | | 2026-10-05 | 16:02 ET | [8-K](/filings/0001731122-26-001312.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001731122-26-001312 | | 2026-09-24 | 16:11 ET | [8-K](/filings/0001731122-26-001281.md) | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 9.01 Financial statements and exhibits | 0001731122-26-001281 | | 2026-09-22 | 16:10 ET | [8-K](/filings/0001731122-26-001271.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001731122-26-001271 | | 2026-08-31 | 16:06 ET | [8-K](/filings/0001731122-26-001173.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001731122-26-001173 | | 2026-08-28 | 16:33 ET | [8-K](/filings/0001731122-26-001170.md) | 3.02 Unregistered sale of equity | 0001731122-26-001170 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001731122-26-000577.md), filed Apr 15, 2026. ## Forecast league Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/d660d41e-1bdf-4420-9d1f-572111395053) ## About the filer - CIK: 1553788 - Tickers: EDVA - Exchange: NYSE - SIC code: 2080 Beverages - State of incorporation: NV - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 27, 2026, 17:31 ET. No prices; not investment advice.